On this page
Read the experiment
The finding and its boundary
The study reported counteraction of morphine-related analgesia, while BPC-157 alone did not show analgesia in that test. This is not evidence of pain relief in human patients.
Gastric pentadecapeptide BPC 157 counteracts morphine-induced analgesia in mice.
- Experiment
- Experimental animal investigation with the intervention and outcomes specified in the indexed abstract.
- Study system
- Mice tested with morphine, naloxone and dopamine-related pharmacologic manipulation
- Measured outcome
- Hot-plate reaction time
- Reported result
- The study reported counteraction of morphine-related analgesia, while BPC-157 alone did not show analgesia in that test.
- What this cannot establish
- This is not evidence of pain relief in human patients.
What was actually tested
Mice tested with morphine, naloxone and dopamine-related pharmacologic manipulation. The investigators measured hot-plate reaction time. The study reported counteraction of morphine-related analgesia, while BPC-157 alone did not show analgesia in that test.
The detail that changes the takeaway
A result can run against a broad marketing narrative. Here the relevant observation is not simply more pain relief. The direction of the interaction and the lack of an analgesic effect by the peptide alone should stay visible instead of being absorbed into a generic pain-management claim.
How far the result travels
This is not evidence of pain relief in human patients.
A useful comparison
BPC-157 in ketamine-related behavioral tests examines object recognition, open-field, sucrose and social-behavior measures. Here, the measured endpoint was hot-plate reaction time. Those outcomes belong to separate experiments; one is not a replication or a human confirmation of the other. Compare that distinction with the Can one BPC-157 study support the product in front of you? appraisal.
References & product documents
The evidence and service information used here.